Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

SAN CARLOS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has repurchased 32%, or $100.0 million, of its outstanding convertible debt for approximately 48 cents on the dollar, for a total purchase price of $47.8 million. The company also reported its financial results for the third quarter and nine-months ended September 30, 2008.

"The turnaround at Nektar is now largely complete," said Nektar President and CEO Howard W. Robin. "We have created one of the most robust pipelines in biotech, dramatically improved the company's financial strength, assembled a new management team with a solid track record, and refocused the business around our powerful polymer and conjugate chemistry drug development platform."

Third Quarter 2008 Financial Results

Cash, cash equivalents, and short-term investments were $344.5 million at September 30, 2008 compared to $373.9 million at June 30, 2008.

Revenue for the three month period ended September 30, 2008 was $21.4 million compared to revenue of $56.3 million in the third quarter of 2007. For the first nine months of 2008, revenue was $61.8 million as compared to $207.3 million in the same period of 2007. This decrease in revenue is primarily the result of lower product manufacturing revenues due to the termination of the inhaled insulin collaboration by Pfizer in late 2007.

Nektar has continued to make significant improvements to its operating efficiencies as compared to a year ago. For the first nine months of 2008, the company's general and administrative expense was $37.0 million as compared to $42.3 million for the same period a year ago. Research and development expense was $109.1 million in the first nine months of 2008 as compared to $114.3 million for the same period in 2007. Included in the $109.1 million of overall research and development spending is approximately $66.0 million of new investments in Nektar preclinical and clinical development programs.

Nektar reported a net loss for the quarter ended September 30, 2008 of $37.0 million or $0.40 per share, compared to a net loss of $18.6 million or $0.20 per share in the third quarter of 2007. For the first nine months of 2008, the company reported a net loss of $111.1 million or $1.20 per share, compared to a net loss of $71.8 million or $0.78 per share for the same period in 2007.

Conference Call to Discuss Third Quarter 2008 Financial Results

Nektar will host a conference call today for analysts and investors at 2:00 p.m. Pacific time to discuss the company's third quarter performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor Relations section of the Nektar website, The web broadcast of the conference call will be available for replay through November 20, 2008.

To access the conference call, follow these instructions:

Dial: 866-362-4666 (U.S.); 617-597-5313 (international)

Participant Passcode: 63756947 (Howard Robin is the host)

Audio replay dial-in and passcode:

To access the replay, follow these instructions:

Dial: 888-286-8010 (U.S.); 617-801-6888 (international)

Participant Passcode: 41304675

Nektar to Host Annual R&D Day on November 12

Nektar will host its second annual R&D Day meeting on Wednesday, November 12, 2008 from 12:00 pm to 3:30 pm Eastern time at the InterContinental Hotel in New York City. For more information or to RSVP for this event, please visit the investor relations section of the company's website at

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and conjugate chemistry technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

For more information on Nektar Therapeutics, please visit

This press release contains forward-looking statements that reflect the company's current views regarding the status of the company's turnaround, the potential, progress, and clinical plans for the company's proprietary and partnered product pipeline, the value and potential of the company's technology platforms, and the company's financial strength. These forward- looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of its partners are in various stages of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) clinical trials are long, expensive and uncertain processes and the risk of failure of any product that is in clinical development and prior to regulatory approval remains high and can occur at any stage due to efficacy, safety or other factors; , and (iv) the risk that the sale of the company's pulmonary business assets to Novartis Pharmaceuticals Corporation may not close or the closing may be delayed, (v) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (vi) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates or complex commercial agreements. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Stephan Herrera, 415-488-7699

Jennifer Ruddock, 650-631-4954



(In thousands, except per share information)

Unaudited Unaudited

Three-Months Ended Nine-Months Ended

September 30, September 30,

2008 2007 2008 2007


Product sales and royalties $9,474 $37,497 $28,855 $159,818

Contract research 11,965 18,824 32,977 47,436

Total revenue 21,439 56,321 61,832 207,254

Operating costs and expenses:

Cost of goods sold 5,349 27,457 18,020 123,469

Cost of idle Exubera

manufacturing capacity 6,821

Research and development 38,265 35,773 109,138 114,265

General and administrative 12,149 12,426 36,951 42,339

Amortization of other

intangible assets 237 237 710 710

Total operating costs and

expenses 56,000 75,893 171,640 280,783

Loss from operations (34,561) (19,572) (109,808) (73,529)

Non-operating income (expense):

Interest income 2,375 5,519 10,578 16,444

Interest expense (3,988) (4,773) (11,835) (14,408)

Loss on equity investment (705) - (705) -

Other income (expense), net 117 206 1,188 189

Total non-operating income

(expense) (2,201) 952 (774) 2,225

Loss before provision for income

taxes (36,762) (18,620) (110,582) (71,304)

Provision for income taxes 276 - 536 500

Net loss $(37,038) $(18,620) $(111,118) $(71,804)

Basic and diluted net loss per

share $(0.40) $(0.20) $(1.20) $(0.78)

Shares used in computing basic

and diluted net loss per share 92,415 92,028 92,408 91,764



(In thousands)

September 30, December 31,

2008 2007

(unaudited) (1)


Current assets:

Cash and cash equivalents $63,713 $76,293

Short-term investments 280,803 406,060

Accounts receivable, net of allowance 8,515 21,637

Inventory 9,861 12,187

Assets held for sale 42,975 -

Other current assets 4,420 7,106

Total current assets 410,287 523,283

Property and equipment, net 73,641 114,420

Goodwill 78,431 78,431

Other intangible assets, net 1,971 2,680

Other assets 4,022 6,289

Total assets $568,352 $725,103


Current liabilities:

Accounts payable $2,113 $3,589

Accrued compensation 14,723 14,680

Accrued expenses to contract manufacturers - 40,444

Accrued expenses 15,715 12,446

Interest payable 85 2,638

Capital lease obligations, current portion 1,401 2,335

Deferred revenue, current portion 11,970 19,620

Other current liabilities 2,515 2,340

Total current liabilities 48,522 98,092

Convertible subordinated notes 315,000 315,000

Capital lease obligations 20,689 21,632

Deferred revenue 57,027 61,349

Deferred gain 7,323 8,680

Other long-term liabilities 11,159 5,911

Total liabilities 459,720 510,664

Commitments and contingencies

Stockholders' equity:

Preferred stock - -

Common stock 9 9

Capital in excess of par value 1,309,973 1,302,541

Accumulated other comprehensive income (478) 1,643

Accumulated deficit (1,200,872) (1,089,754)

Total stockholders' equity 108,632 214,439

Total liabilities and stockholders' equity $568,352 $725,103

(1) The consolidated balance sheet at December 31, 2007 has been derived

from the audited financial statements at that date but does not

include all of the information and notes required by generally

accepted accounting principles in the United States for complete

financial statements. Certain 2007 amounts have been reclassified

between line items to conform with the 2008 presentation.



(In thousands, except per share information)


Nine Months Ended

September 30,

2008 2007

Cash flows used in operating activities:

Net loss $(111,118) $(71,804)

Adjustments to reconcile net loss to

net cash used in operating activities:

Stock-based compensation 6,955 11,712

Depreciation and amortization 18,610 22,964

Loss on equity investment 705 -

Foreign currency transaction loss 428 -

Loss on sale or disposal of assets 282 1,776

Amortization of gain related to sale of building (656) (656)

Changes in assets and liabilities:

Decrease (increase) in trade accounts receivable 13,122 10,343

Decrease (increase) in inventories 2,326 (2,519)

Decrease (increase) in prepaids and other assets 2,659 6,846

Increase (decrease) in accounts payable (1,476) (2,784)

Increase (decrease) in accrued compensation (229) (2,170)

Increase (decrease) in accrued

expenses to contract manufacturers (40,444) -

Increase (decrease) in accrued expenses 3,269 6,622

Increase (decrease) in interest payable (2,553) (2,684)

Increase (decrease) in deferred revenue (11,972) 61,777

Increase (decrease) in other liabilities 5,027 152

Net cash used in operating activities (115,065) 39,575

Cash flows from investing activities:

Purchases of investments (411,417) (342,807)

Maturities of investments 506,348 468,245

Sales of investments 28,590 -

Purchases of property and equipment (15,064) (21,030)

Investment in Pearl Therapeutics Inc. (4,236) -

Net cash provided by investing activities 104,221 104,408

Cash flows used in financing activities:

Repayments of convertible subordinated notes - (36,026)

Payments of loan and capital lease

obligations (1,910) (787)

Proceeds from issuance of common

stock related to employee stock

option exercises and employee stock

purchase plan 477 3,479

Net cash used in financing activities (1,433) (33,334)

Effect of exchange rates on cash and

cash equivalents (303) 304

Net increase (decrease) in cash and

cash equivalents $(12,580) $110,953

Cash and cash equivalents at beginning of period $76,293 $63,760

Cash and cash equivalents at end of period $63,713 $174,713

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: